Agomab to present STENOVA extension data at UEG Week

Agomab said open-label extension data from its Phase 2a STENOVA study of ontunisertib will be presented at UEG Week 2026. The company also plans a scientific symposium on fibro-inflammation and said the results support starting its Phase 2b NOV-ERA study.